Cerus (NASDAQ:CERS) Share Price Crosses Above 200 Day Moving Average – What’s Next?

Cerus Corporation (NASDAQ:CERS) shares crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.35 and traded as high as $1.53. Cerus shares last traded at $1.51, with a volume of 1,394,861 shares changing hands.

Cerus Trading Down 0.7%

The firm has a market cap of $289.47 million, a P/E ratio of -15.10 and a beta of 1.70. The company has a quick ratio of 1.35, a current ratio of 2.00 and a debt-to-equity ratio of 1.01. The firm’s 50-day simple moving average is $1.32 and its 200 day simple moving average is $1.35.

Cerus (NASDAQ:CERS) last announced its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The company had revenue of $60.10 million during the quarter, compared to the consensus estimate of $51.80 million. Cerus had a negative return on equity of 33.77% and a negative net margin of 9.81%. Cerus has set its FY 2025 guidance at EPS. As a group, analysts expect that Cerus Corporation will post -0.08 earnings per share for the current year.

Institutional Trading of Cerus

Several hedge funds have recently added to or reduced their stakes in CERS. AQR Capital Management LLC raised its position in Cerus by 291.6% in the first quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock worth $1,986,000 after acquiring an additional 1,064,133 shares during the period. Acadian Asset Management LLC grew its stake in Cerus by 112.5% during the first quarter. Acadian Asset Management LLC now owns 1,898,621 shares of the biotechnology company’s stock valued at $2,637,000 after acquiring an additional 1,005,079 shares in the last quarter. Nuveen LLC purchased a new position in Cerus during the first quarter valued at approximately $643,000. Qube Research & Technologies Ltd grew its stake in Cerus by 156.5% during the second quarter. Qube Research & Technologies Ltd now owns 749,564 shares of the biotechnology company’s stock valued at $1,057,000 after acquiring an additional 457,347 shares in the last quarter. Finally, Millennium Management LLC grew its stake in Cerus by 12.0% in the 1st quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock worth $4,479,000 after buying an additional 344,395 shares in the last quarter. Institutional investors own 78.37% of the company’s stock.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.